Closed-Loop tACS for Major Depressive Disorder (MDD)
NIMH, R43MH119872
This project is developing and evaluating targeted, closed-loop brain stimulation for psychiatric indications.
Our Proof of Concept Trial found that 80% of patients were found to be free of clinical depression symptoms when assessed by a psychiatrist two weeks after completing treatment.
FDA Breakthrough Device designation for the treatment of MDD.
Pivotal Clinical Trial to launch in 2025.
This project is developing and evaluating targeted, closed-loop brain stimulation for psychiatric indications.
Our Proof of Concept Trial found that 80% of patients were found to be free of clinical depression symptoms when assessed by a psychiatrist two weeks after completing treatment.
FDA Breakthrough Device designation for the treatment of MDD.
Pivotal Clinical Trial to launch in 2025.
Substance Use Disorder
NIDA, R43DA054848
This project develops and evaluates a modified form of tACS as a potential non-invasive brain stimulation treatment for substance use disorder (SUD).
An initial feasibility trial has been completed and further development is on-going.
This project develops and evaluates a modified form of tACS as a potential non-invasive brain stimulation treatment for substance use disorder (SUD).
An initial feasibility trial has been completed and further development is on-going.